Home > Insider Trading > Filing (0000899243-17-027009)

Filing Details

Accession Number:: 0000899243-17-027009
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2017-11-20 17:37:04
Reporting Period:: 2017-11-20

Accepted Time:: 2017-11-20 17:37:04
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1501697	Arsanis Inc.	ASNS	()	DE

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1460732	Sv Life Sciences Fund V Lp	One Boston Place, Suite 3900, 201 Washington Street Boston MA 02108	No	No	Yes	No
1482194	Sv Life Sciences Fund V Strategic Partners, L.p.	One Boston Place, Suite 3900, 201 Washington Street Boston MA 02108	No	No	Yes	No
1642251	Sv Life Sciences Fund Vi, L.p.	One Boston Place, Suite 3900, 201 Washington Street Boston MA 02108	No	No	Yes	No
1644160	Svlsf V, Llc	One Boston Place, Suite 3900 201 Washington Street Boston MA 02108	No	No	Yes	No
1667605	Sv Life Sciences Fund Vi Strategic Partners, L.p.	One Boston Place, Suite 3900, 201 Washington Street Boston MA 02108	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2017-11-20	19,128	$0.00	19,128	No	4	C	Direct
Common Stock	Acquisiton	2017-11-20	404	$0.00	19,532	No	4	C	Direct
Common Stock	Acquisiton	2017-11-20	247,010	$0.00	266,542	No	4	C	Direct
Common Stock	Acquisiton	2017-11-20	5,219	$0.00	271,761	No	4	C	Direct
Common Stock	Acquisiton	2017-11-20	322,102	$0.00	593,863	No	4	C	Direct
Common Stock	Acquisiton	2017-11-20	6,806	$0.00	600,669	No	4	C	Direct
Common Stock	Acquisiton	2017-11-20	111,955	$0.00	712,624	No	4	C	Direct
Common Stock	Acquisiton	2017-11-20	2,365	$0.00	714,989	No	4	C	Direct
Common Stock	Acquisiton	2017-11-20	202,915	$0.00	917,904	No	4	C	Direct
Common Stock	Acquisiton	2017-11-20	4,288	$0.00	922,192	No	4	C	Direct
Common Stock	Acquisiton	2017-11-20	431,980	$0.00	1,354,172	No	4	C	Direct
Common Stock	Acquisiton	2017-11-20	14,789	$0.00	1,368,961	No	4	C	Direct
Common Stock	Acquisiton	2017-11-20	483,448	$10.00	1,852,409	No	4	P	Direct
Common Stock	Acquisiton	2017-11-20	16,552	$10.00	1,868,961	No	4	P	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	P	Direct
No	4	P	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Convertible Preferred Stock	Disposition	2017-11-20	65,287	$0.00	19,128	$0.00
Common Stock	Series A-1 Convertible Preferred Stock	Disposition	2017-11-20	1,380	$0.00	404	$0.00
Common Stock	Series A-2 Convertible Preferred Stock	Disposition	2017-11-20	690,259	$0.00	247,010	$0.00
Common Stock	Series A-2 Convertible Preferred Stock	Disposition	2017-11-20	14,587	$0.00	5,219	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2017-11-20	721,402	$0.00	322,102	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2017-11-20	15,246	$0.00	6,806	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2017-11-20	224,665	$0.00	111,955	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2017-11-20	4,747	$0.00	2,365	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2017-11-20	692,552	$0.00	202,915	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2017-11-20	14,635	$0.00	4,288	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2017-11-20	1,474,348	$0.00	431,980	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2017-11-20	50,477	$0.00	14,789	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct
No	4	C	Direct

Footnotes

The Series A-1 Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.
The Series A-2 Convertible Preferred Stock converted into Common Stock on a 0.35785-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.
The Series B Convertible Preferred Stock converted into Common Stock on a 0.44650-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.
The Series C Convertible Preferred Stock converted into Common Stock on a 0.49832-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series C Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.
The Series D Convertible Preferred Stock converted into Common Stock on a 0.29300-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D Convertible Preferred Stock was convertible at any time at the holder's election and automatically upon the closing at the Issuer's initial public offering. The shares had no expiration date.
These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.
These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SVLS V GP is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III and Michael Ross are members of the investment committee of SVLSF V, LLC. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.
These shares are owned directly by SV Life Sciences Fund VI, L.P. ("SVLS VI LP"). SV Life Sciences Fund VI (GP), LP ("SVLS VI GP") is the general partner of SVLS VI LP. The general partner of SVLS VI GP is SVLSF VI, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III, Paul LaViolette, Thomas Flynn and Michael Ross are members of the investment committee of SVLSF VI, LLC. SVLS VI GP, SVLSF VI, LLC and each of the individuals comprising the SVLSF VI, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS VI LP. Each of SVLS VI GP, SVLSF VI, LLC and the individual members of the SVLSF VI, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.
These shares are owned directly by SV Life Sciences Fund VI Strategic Partners, L.P. ("SVLS VI SPP"). SVLS VI GP is the general partner of SVLS VI SPP. The general partner of SVLS VI GP is SVLSF VI, LLC. Kate Bingham, James Garvey, Eugene D. Hill, III, Paul LaViolette, Thomas Flynn, and Michael Ross are members of the investment committee of SVLSF VI, LLC. SVLS VI GP, SVLSF VI, LLC and each of the individuals comprising the SVLSF VI, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS VI SPP. Each of SVLS VI GP, SVLSF VI, LLC and the individual members of the SVLSF VI, LLC investment committee disclaims beneficial ownership of these securities and this report shall not be deemed to be an admission that any one of them is the beneficial owner of such securities for purposes of Section 16 or any other purpose, except to the extent of their pecuniary interest therein.